Concerns about HAART (Highly Active Anti-Retroviral Therapy)

Alberta Reappraising AIDS Society

David R. Crowe, President
Phone: +1-403-289-6609
Fax: +1-403-206-7717
Email: David.Crowe@aras.ab.ca

Roger Swan, Treasurer
Box 61037, Kensington Postal Outlet
Calgary, Alberta T2N 4S6
Canada
Office
Phone: +1-403-220-0129
Email: aras@aras.ab.ca
Web: noaids.ca

Concerns about HAART (Highly Active Anti-Retroviral Therapy)

HAART is the therapy, composed of multiple anti-HIV drugs, that is prescribed to many HIV-positive people, even before they develop symptoms of AIDS (and without considering that many will never develop these symptoms). The therapy usually includes one nucleoside analog (DNA chain terminator), one protease inhibitor and either a second nucleoside analog (“nuke”) or a non-nucleoside reverse transcription inhibitor (NNRTI).

The quotes are categorized as:

  • Acceptance
  • Adherence/Compliance
  • Other Adverse Effects
  • Adverse Effects with Nucleoside Analogs (‘Nukes’)
  • Auxiliary Therapy
  • Blood Disorders (Anemia etc.)
  • Bone Disease
  • Cancer
  • Drug company disclaimers
  • Heart Disease
  • Ineffectiveness
  • Immune Restitution Disease (IRD) or Immune Restoration Inflammatory Syndrome (IRIS)
  • Kidney Damage (Nephrotoxicity)
  • Liver Damage
  • HAART for a Life Time (not a Good Time)?
  • Metabolic Disorders
  • Mitochondria
  • Muscle Damage
  • Neurological and Brain Damage
  • Nevirapine
  • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
  • Non-HIV Benefits of HAART
  • Health Without Toxic Therapies
  • Post-Exposure Prophylaxis (PEP)
  • Mothers & Children
  • Protease Inhibitors
  • Resistance to Therapy
  • Rashes and Other Skin Problems
  • Usage Trends
  • Feedback

    We appreciate your comments, feedback, questions and suggestions for improvements to this site. Click here to send us a message.

    © Copyright September 7, 2014: Alberta Reappraising AIDS Society